检索结果 - Katja Weisel

Refine Results
  1. 1
    OP9 Stroma Augments Survival of Hematopoietic Precursors and Progenitors During Hematopoietic Differentiation from Human Embryonic Stem Cells

    OP9 Stroma Augments Survival of Hematopoietic Precursors and Progenitors During Hematopoietic Differentiation from Human Embryonic Stem Cells 由 Junfeng Ji, Kausalia Vijayaragavan, Marc Bossé, Katja Weisel, Mickie Bhatia

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

    Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma 由 Jakub Radocha, Niels W.C.J. van de Donk, Katja Weisel

    出版 2021
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  3. 3
    European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial

    European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial 由 Colin A. Hutchison, Mark Cook, Nils Heyne, Katja Weisel, Lucinda Billingham, A.R. Bradwell, Paul Cockwell

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany

    T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany 由 Paymon Ahmadi, Winfried Alsdorf, Lisa Leypoldt, Ricardo Kosch, Christoph Schaefers, Nico Gagelmann, Francis Ayuk, Florian Kron, Katja Weisel

    出版 2025
    获取全文
    Carta
    加到收藏夹
    Saved in:
  5. 5
    Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence

    Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence 由 Monique Hartley-Brown, Katja Weisel, Jacopo Bitetti, John A. Carter, Simon McNamara, Molly Purser, Antonio Palumbo, Paul G. Richardson

    出版 2024
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  6. 6
    Outcome of critically ill patients receiving systemic chemotherapy on the intensive care unit

    Outcome of critically ill patients receiving systemic chemotherapy on the intensive care unit 由 Panagiotis Karagiannis, Felix Klingler, Viktor Arelin, Winfried Alsdorf, Christina König, Kevin Roedl, Walter Fiedler, Katja Weisel, Stefan Kluge, Carsten Bokemeyer, Dominic Wichmann

    出版 2025
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

    The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development 由 Pralay Mukhopadhyay, Hesham Abdullah, Joanna Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, María‐Victoria Mateos, Meletios Α. Dimopoulos, Sagar Lonial

    出版 2025
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  8. 8
    Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

    Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study 由 Saad Z. Usmani, Hang Quach, María‐Victoria Mateos, Ola Landgren, Xavier Leleu, David S. Siegel, Katja Weisel, Xiaomei Shu, Chuang Li, Meletios Α. Dimopoulos

    出版 2023
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

    Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis... 由 Saad Z. Usmani, Hang Quach, María‐Victoria Mateos, Ola Landgren, Xavier Leleu, David S. Siegel, Katja Weisel, Hui Yang, Zandra Klippel, Anita Zahlten‐Kumeli, Meletios Α. Dimopoulos

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial

    Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the random... 由 Meletios Α. Dimopoulos, Sagar Lonial, Keith A. Betts, Clara Chen, Miriam L. Zichlin, Alexander Brun, James Signorovitch, Dinara Makenbaeva, Sabeen Mekan, Oumar Sy, Katja Weisel, Paul G. Richardson

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial

    High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial 由 Colin A. Hutchison, Paul Cockwell, V. V. Moroz, A.R. Bradwell, Lesley Fifer, Julian D. Gillmore, Mark Jesky, Markus Storr, Julie Wessels, Christopher G. Winearls, Katja Weisel, Nils Heyne, Mark Cook

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the <scp>OPTIMISMM</scp> Trial

    Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the <scp>OPTIM... 由 Paul G. Richardson, Meral Beksaç, Albert Oriol, Jindriska Lindsay, Fredrik Schjesvold, Mónica Galli, Münci Yağcı, Alessandra Larocca, Katja Weisel, Xin Yu, Cynthia Donahue, Jorge Acosta‐Reyes, Teresa Peluso, Meletios Α. Dimopoulos

    出版 2025
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    P964: PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD) IN THE DREAMM-3 STUDY

    P964: PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD)... 由 Vânia Hungria, Katja Weisel, Brooke M. Currie, Sue Perera, Neal Sule, Wei He, Astrid McKeown, Sandhya Sapra, Linda Nelsen, Mary Li, Sophie Barale, Julia Boyle, Kaytlyn McPoyle, Meletios Α. Dimopoulos

    出版 2023
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell–based immunotherapy

    The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell–based immunotherapy 由 Simon Walz, Juliane S. Stickel, Daniel J. Kowalewski, Heiko Schuster, Katja Weisel, Linus Backert, Stefan Kahn, Annika Nelde, Tatjana Stroh, Martin Handel, Oliver Kohlbacher, Lothar Kanz, Helmut R. Salih, Hans‐Georg Rammensee, Stefan Stevanović

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    MM-510 Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study

    MM-510 Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexam... 由 Vânia Hungria, Katja Weisel, Brooke M. Currie, Sue Perera, Neal Sule, Wei He, Katherine Davy, Astrid McKeown, Sandhya Sapra, Linda Nelsen, Mary Li, Sophie Barale, Julia Boyle, Kaytlyn McPoyle, Meletios Α. Dimopoulos

    出版 2023
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    POSTER: MM-510 Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study

    POSTER: MM-510 Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Do... 由 Vânia Hungria, Katja Weisel, Brooke M. Currie, Sue Perera, Neal Sule, Wei He, Katherine Davy, Astrid McKeown, Sandhya Sapra, Linda Nelsen, Mary Li, Sophie Barale, Julia Boyle, Kaytlyn McPoyle, Meletios Α. Dimopoulos

    出版 2023
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life

    Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life 由 Evangelos Terpos, Joseph Mıkhael, Roman Hájek, Ajai Chari, Sonja Zweegman, Hans C. Lee, María‐Victoria Mateos, Alessandra Larocca, Karthik Ramasamy, Martin Kaiser, Gordon Cook, Katja Weisel, Caitlin Costello, Jennifer Elliott, Antonio Palumbo, Saad Z. Usmani

    出版 2021
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  18. 18
    PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

    PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULT... 由 Katja Weisel, Vânia Hungria, Hang Quach, Sung‐Soo Yoon, Paula Rodríguez‐Otero, Glenn S. Kroog, Arijit Sinha, Anita Boyapati, Charlotte Lyon, Karen Rodriguez Lorenc, Timothy J. Inocencio, James Harnett, Lei Chi, Vygngley Moore, Peter M. Voorhees

    出版 2023
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes

    Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes 由 Xavier Leleu, Thomas G. Martin, Katja Weisel, Fredrik Schjesvold, Shinsuke Iida, Fabio Malavasi, Salomon Manier, Chang‐Ki Min, Enrique M. Ocio, Charlotte Pawlyn, Aurore Perrot, Hang Quach, Joshua Richter, Ivan Špıčka, Kwee Yong, Paul G. Richardson

    出版 2022
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  20. 20
    Health‐related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial

    Health‐related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethaso... 由 Vânia Hungria, Meral Beksaç, Katja Weisel, Ajay K. Nooka, Tamás Masszi, Ivan Špıčka, Markus Munder, María‐Victoria Mateos, Tomer M. Mark, Ming Qi, Xiang Qin, John Fastenau, Andrew Spencer, Pieter Sonneveld, Wendy Garvin, Thomas Renaud, Katharine S. Gries

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: